TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1491390

Group type: EXPERIMENTAL
Intervention: Chloroquine therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no remittive agents)
Number of subjects: 32
Study: 4006379

Group type: EXPERIMENTAL
Intervention: Uniphyl (two 400 mg tablets) under fasting conditions
Number of subjects: 18

Group type: COMPARATOR
Intervention: Theo-Dur Sprinkle under nonfasting conditions
Number of subjects: 18
Study: 31686742

Group type: EXPERIMENTAL
Intervention: Isosorbide Mononitrate (ISMN) 20 mg/day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 27669731

Group type: EXPERIMENTAL
Intervention: Individual Managing Anger Program (I-MAP), a Cognitive behavioural therapy (CBT) and mindfulness-based anger management intervention
Number of subjects: 24

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 24
Study: 28105463

Group type: EXPERIMENTAL
Intervention: Workplace flexibility/support intervention
Number of subjects: 396

Group type: COMPARATOR
Intervention: Control
Number of subjects: 396
Study: 23754275

Group type: EXPERIMENTAL
Intervention: Nocebo condition (n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control condition (n = 15)
Number of subjects: 30
Study: 23251579

Group type: EXPERIMENTAL
Intervention: FIFA 11+
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: HarmoKnee
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study: 21180002

Group type: EXPERIMENTAL
Intervention: Bleached with resin coating (group BC)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Bleached without resin coating (group B)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Immersed in artificial saliva with resin coating (group SC)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Immersed in artificial saliva without resin coating (group S)
Number of subjects: 160
Study: 17714372

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 15878467

Group type: EXPERIMENTAL
Intervention: Meta-analyses of genetic associations
Number of subjects: 81

Group type: COMPARATOR
Intervention: Meta-analyses of health care interventions
Number of subjects: 81
Study: 11940031

Group type: EXPERIMENTAL
Intervention: Functional Electrical Therapy (FET) - 30 min daily sessions for 3 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Functional Electrical Therapy (FET) - LFG
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group - LFG
Number of subjects: 16
Study: 9616258

Group type: EXPERIMENTAL
Intervention: Pharmacological baroreflex sensitivity (sodium nitroprusside and phenylephrine)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Spontaneous sequences of increasing and decreasing blood pressure and pulse interval
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Spectral analysis to derive alpha, the index of overall baroreflex gain
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pharmacological methods
Number of subjects: 20

Group type: COMPARATOR
Intervention: Spectral baroreflex sensitivity
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sequence methods
Number of subjects: 20
Study: 8592993

Group type: EXPERIMENTAL
Intervention: Single dose of 100 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Single dose of 200 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Single dose of 400 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Single dose of 600 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Multiple doses of 300 mg twice daily for 6.5 days
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Concurrent administration of probenecid
Number of subjects: 13
Study: 2913960

Group type: EXPERIMENTAL
Intervention: Topical methotrexate 0.1%
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Topical methotrexate 0.5%
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Topical methotrexate 1%
Number of subjects: 42

Group type: COMPARATOR
Intervention: Vehicle alone (control)
Number of subjects: 42
Study: 30742522

Group type: EXPERIMENTAL
Intervention: 25% urea cream
Number of subjects: 41

Group type: COMPARATOR
Intervention: sorbolene
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Comparison of both treatments
Number of subjects: 41
Study: 26381118

Group type: EXPERIMENTAL
Intervention: Banded RME
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Acrylic splint RME
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Modified acrylic splint RME
Number of subjects: 42
Study: 25002178

Group type: EXPERIMENTAL
Intervention: Bivalirudin (bolus 0.75 mg/kg; infusion 1.75 mg/kg per hour)
Number of subjects: 1812

Group type: COMPARATOR
Intervention: Heparin (70 U/kg)
Number of subjects: 1812

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 1812

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 1812
Study: 24351495

Group type: EXPERIMENTAL
Intervention: Shared care model
Number of subjects: 164

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 164
Study: 21609832

Group type: EXPERIMENTAL
Intervention: Adaptation of an internal model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repetition of the newly adapted movement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Operant reinforcement through association of the adapted movement with successful error reduction
Number of subjects: 0
Study: 18469248

Group type: EXPERIMENTAL
Intervention: Turmeric supplementation (55 mg oxalate/d for 4 weeks)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cinnamon supplementation (55 mg oxalate/d for 4 weeks)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control treatment (water only)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cinnamon and turmeric supplementation
Number of subjects: 11
Study: 16531835

Group type: EXPERIMENTAL
Intervention: Medical Symptom Validity Test (MSVT) administered to IME patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Volunteers trying their best on the MSVT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Volunteers simulating memory impairment on the MSVT
Number of subjects: 0
Study: 14646679

Group type: EXPERIMENTAL
Intervention: Latanoprost
Number of subjects: 441

Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 441
Study: 11140554

Group type: EXPERIMENTAL
Intervention: Dentifrice containing triclosan/copolymer (Colgate Total)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group used a dentifrice without triclosan/copolymer and interdental cleaning devices
Number of subjects: 39
Study: 10437188

Group type: EXPERIMENTAL
Intervention: Compound Tong Jiang Oral Liquid with Da Huang (TJ)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Qi Yin Oral Liquid (QY)
Number of subjects: 0
Study: 1441852

Group type: EXPERIMENTAL
Intervention: Defibrase thrombolysis
Number of subjects: 157

Group type: COMPARATOR
Intervention: Conventional therapy plus heparin (control)
Number of subjects: 157
Study: 2951807

Group type: EXPERIMENTAL
Intervention: Duovent (200 micrograms fenoterol + 40 micrograms ipratropium bromide)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Fenoterol (400 micrograms)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (80 micrograms)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 30027160

Group type: EXPERIMENTAL
Intervention: Verbal and/or written dietary advice (VWDA) in group A
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Verbal and/or written dietary advice (VWDA) in both groups
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Group A (VWDA) at T5
Number of subjects: 75
Study: 26280588

Group type: EXPERIMENTAL
Intervention: Polyaxial implants
Number of subjects: 59

Group type: COMPARATOR
Intervention: Monoaxial dorsal fixators
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Laminectomy
Number of subjects: 59

Group type: COMPARATOR
Intervention: No laminectomy
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Cement-augmented screws in patients 60 years or older
Number of subjects: 59

Group type: COMPARATOR
Intervention: Non-cement-augmented screws in patients 60 years or older
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Monoaxial implant, cement-augmented, without laminectomy in patients 60 years or older
Number of subjects: 59
Study: 24885354

Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone before the first radiotherapy and three days placebo thereafter
Number of subjects: 411

Group type: EXPERIMENTAL
Intervention: Four days 8 mg dexamethasone
Number of subjects: 411

Group type: COMPARATOR
Intervention: Daily placebo for four days
Number of subjects: 411
Study: 22280855

Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI) TUR
Number of subjects: 148

Group type: COMPARATOR
Intervention: White Light (WL) TUR
Number of subjects: 148
Study: 20581392

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 433

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 433
Study: 18343806

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir monotherapy
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Triple combination (lopinavir/ritonavir + zidovudine + lamivudine)
Number of subjects: 10
Study: 16542199

Group type: EXPERIMENTAL
Intervention: Oral ibuprofen
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Topical ibuprofen
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 12657404

Group type: EXPERIMENTAL
Intervention: Thiopental sodium 5 mg/kg (Group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg (Group 2)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Etomidate 0.3 mg/kg (Group 3)
Number of subjects: 60
Study: 11253341

Group type: EXPERIMENTAL
Intervention: Immediate mobilization and ambulation, external compression therapy, early Low Molecular Weight Heparin (LMWH) administration, and late oral anticoagulation.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prolonged bed-rest
Number of subjects: 0
Study: 9190049

Group type: EXPERIMENTAL
Intervention: Recognition of names of former students
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Retention interval
Number of subjects: 1
Study: 1286052

Group type: EXPERIMENTAL
Intervention: Lidocaine (0.05%, 0.5%, 1%, and 2%)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Mepivacaine (0.05%, 0.5%, 1%, and 2%)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Bupivacaine (0.025%, 0.25%, 0.5%, and 0.75%)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8

Group type: COMPARATOR
Intervention: Needle stick (no injection)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline with epinephrine (5 micrograms/ml)
Number of subjects: 8
Study: 3084954

Group type: EXPERIMENTAL
Intervention: Reproterol infusion (0.2‐2.0 micrograms/kg/min in Saline)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Salbutamol inhalation (75 micrograms/kg in 2 ml Saline every two hours)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Reproterol infusion (2.0 micrograms/kg/min)
Number of subjects: 20
Study: 30125462

Group type: EXPERIMENTAL
Intervention: Everolimus with reduced tacrolimus (EVR/rTAC) and steroid elimination
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard tacrolimus with mycophenolate mofetil (sTAC/MMF) and steroids
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Everolimus with reduced tacrolimus (EVR/rTAC)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard tacrolimus with mycophenolate mofetil (sTAC/MMF)
Number of subjects: 106
Study: 27797674

Group type: EXPERIMENTAL
Intervention: Soy protein with 66 mg of isoflavones (SPI)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Soy protein alone without isoflavones (SP)
Number of subjects: 200
Study: 26001289

Group type: EXPERIMENTAL
Intervention: Lenalidomide (LEN) treatment
Number of subjects: 13
Study: 23558738

Group type: EXPERIMENTAL
Intervention: Temoporfin PDT (T‐PDT) plus stenting
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Temoporfin PDT (T‐PDT)
Number of subjects: 11
Study: 21646584

Group type: EXPERIMENTAL
Intervention: Coaching focused on asthma home management and outpatient asthma monitoring visits (intervention group)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 241
Study: 19194127

Group type: COMPARATOR
Intervention: Conventional carboplatin plus etoposide (CE) - carboplatin AUC 5 on day 1 IV and etoposide 140 mg/m IV on days 1-3, q28 days
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Dose-intensified carboplatin plus etoposide plus lenograstim - carboplatin AUC 5 on day 1 IV and etoposide 190 mg/m days 1-3 IV with lenograstim 263 microg subcutaneously on days 4-13, q21 days
Number of subjects: 79
Study: 17047930

Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Number of subjects: 145

Group type: COMPARATOR
Intervention: Placebo lozenge
Number of subjects: 145
Study: 15012621

Group type: EXPERIMENTAL
Intervention: Spironolactone plus finasteride (100 mg/day + 5 mg/day)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Spironolactone (100 mg/day) alone
Number of subjects: 65
Study: 11879339

Group type: EXPERIMENTAL
Intervention: Monotherapy (400 mg CBZ per day)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Polytherapy (200 mg CBZ plus 300 mg VPA per day)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Monotherapy
Number of subjects: 130

Group type: COMPARATOR
Intervention: Polytherapy
Number of subjects: 130
Study: 9324482

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 0
Study: 8334827

Group type: EXPERIMENTAL
Intervention: Indomethacin (1 mg kg‐1)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Metoprolol (1.5 mg kg‐1)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 3595669

Group type: EXPERIMENTAL
Intervention: Regimen A: procarbazine (100 mg/m2 p.o., max 150 mg) days 1-10, vindesine (3 mg/m2 i.v., max 5 mg) days 1 and 8, CCNU (150 mg/m2 p.o., max 200 mg) day 1
Number of subjects: 43

Group type: COMPARATOR
Intervention: Regimen B: procarbazine (100 mg/m2 p.o., max 150 mg) days 1-10, DTIC (250 mg/m2 i.v. max 400 mg) days 1-5, CCNU (150 mg/m2 p.o. max 200 mg) day 1
Number of subjects: 43
Study: 31579919

Group type: EXPERIMENTAL
Intervention: Primary surgery for unilateral cleft lip and palate
Number of subjects: 425
Study: 30232866

Group type: EXPERIMENTAL
Intervention: Thermosensitive moxibustion (TSM), applied to bilateral Taichong (LR 3) and Qiuxu (GB 40) once daily for 15 days.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Medication group (Estazolam tablets, 1 mg/d, once daily for 15 days).
Number of subjects: 60
Study: 27058964

Group type: EXPERIMENTAL
Intervention: Single HA injection
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Double HA injection
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Stabilization splint therapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (self-selected)
Number of subjects: 51
Study: 24704800

Group type: EXPERIMENTAL
Intervention: Pro‐Self(©) Plus Pain Control Program
Number of subjects: 0
Study: 22846453

Group type: EXPERIMENTAL
Intervention: Moderate-intensity endurance exercise
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard care control (encouragement to exercise only)
Number of subjects: 28
Study: 20932576

Group type: EXPERIMENTAL
Intervention: Cumulative risk index comprised of seven risk indicators
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Incremental increase in cumulative risk
Number of subjects: 252
Study: 18625670

Group type: EXPERIMENTAL
Intervention: Dosimeter method
Number of subjects: 27
Study: 16141746

Group type: EXPERIMENTAL
Intervention: Exercise training for 3 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Minimal activity control program
Number of subjects: 44
Study: 11994561

Group type: EXPERIMENTAL
Intervention: Advanced prostate cancer patients (androgen ablated)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy elderly males (mean age, 77 years)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy age-matched controls
Number of subjects: 30
Study: 10026684

Group type: EXPERIMENTAL
Intervention: Clinical pathway (92 patients)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group (71 patients)
Number of subjects: 163
Study: 7593728

Group type: EXPERIMENTAL
Intervention: Moclobemide (300-600 mg daily)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Fluoxetine (20-40 mg daily)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 70

Group type: COMPARATOR
Intervention: Moclobemide and Fluoxetine
Number of subjects: 70
Study: 2344514

Group type: EXPERIMENTAL
Intervention: Digital rectal examination by a urologist or general practitioner
Number of subjects: 1494
Study: 7026542

Group type: EXPERIMENTAL
Intervention: Phenelzine (mean 81 mg/day)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Imipramine (mean 144 mg/day)
Number of subjects: 43
Study: 31584032

Group type: EXPERIMENTAL
Intervention: Capillary tips
Number of subjects: 34

Group type: COMPARATOR
Intervention: Disposable needle
Number of subjects: 34

Group type: COMPARATOR
Intervention: Pastinject
Number of subjects: 34
Study: 30215460

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral TAP block using 40 mL 0.25% bupivacaine
Number of subjects: 88

Group type: COMPARATOR
Intervention: Standard analgesia protocol without TAP block
Number of subjects: 88
Study: 27184353

Group type: EXPERIMENTAL
Intervention: Edwards Sapien 3 (ES3) valve
Number of subjects: 209

Group type: COMPARATOR
Intervention: Edwards Sapien XT (ESXT) valve
Number of subjects: 209
Study: 24448735

Group type: EXPERIMENTAL
Intervention: Reward-related stop trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reward availability
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reward information
Number of subjects: 0
Study: 22823027

Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Continued protease inhibitor (PI) or non-nucleoside reverse transcriptase inhibitor (NNRTI)
Number of subjects: 36
Study: 19106322

Group type: EXPERIMENTAL
Intervention: Breast-feeding promotion intervention
Number of subjects: 17046

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 17046
Study: 17980239

Group type: EXPERIMENTAL
Intervention: Detergent and chlorhexidine‐alcohol (A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Detergent (B)
Number of subjects: 50
Study: 15492316

Group type: EXPERIMENTAL
Intervention: AGTR2 G1675A polymorphism
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: ACE D/I polymorphism
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Sodium excretion
Number of subjects: 221

Group type: COMPARATOR
Intervention: AGTR1 A1166C polymorphism
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: AGTR2 polymorphism
Number of subjects: 221
Study: 12017948

Group type: EXPERIMENTAL
Intervention: 200 mg of fenticonazole nitrate intravaginal ovules
Number of subjects: 80

Group type: COMPARATOR
Intervention: 400 mg of myconazole vaginal ovules
Number of subjects: 80
Study: 10570201

Group type: EXPERIMENTAL
Intervention: T2* magnetic resonance microscopy (MRM)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Diffusion magnetic resonance microscopy (MRM)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Nondemented controls
Number of subjects: 8
Study: 7776934

Group type: EXPERIMENTAL
Intervention: rhDNase (2.5 mg once daily)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo (once daily)
Number of subjects: 3
Study: 1983214

Group type: EXPERIMENTAL
Intervention: Topical oxatomide gel 5%
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 112068

Group type: EXPERIMENTAL
Intervention: Diflunisal 500 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31796263

Group type: EXPERIMENTAL
Intervention: Previsit educational materials about individual insurance plans
Number of subjects: 100

Group type: COMPARATOR
Intervention: No previsit educational materials (control group)
Number of subjects: 100
Study: 31255395

Group type: EXPERIMENTAL
Intervention: Cocaine (300 mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 28093837

Group type: EXPERIMENTAL
Intervention: Single-dose simulation education with structured debriefing and verbal feedback
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract)
Number of subjects: 30
Study: 25583184

Group type: EXPERIMENTAL
Intervention: Parachute
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Hand paddles + parachute
Number of subjects: 13

Group type: COMPARATOR
Intervention: Hand paddles
Number of subjects: 13

Group type: COMPARATOR
Intervention: Without equipment
Number of subjects: 13
Study: 23998969

Group type: EXPERIMENTAL
Intervention: OM3‐FFA 2 g/d
Number of subjects: 647

Group type: EXPERIMENTAL
Intervention: OM3‐FFA 4 g/d
Number of subjects: 647

Group type: COMPARATOR
Intervention: Control (olive oil [OO] 4 g/d)
Number of subjects: 647
Study: 21871414

Group type: EXPERIMENTAL
Intervention: Prolotherapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Corticosteroid injection
Number of subjects: 24
Study: 19233338

Group type: EXPERIMENTAL
Intervention: Ocular suppression during spatial serial recall task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Articulatory suppression combined with spatial serial recall task
Number of subjects: 0
Study: 17279428

Group type: EXPERIMENTAL
Intervention: Shunt Design Trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endoscopic Shunt Insertion Trial
Number of subjects: 0
Study: 15521903

Group type: EXPERIMENTAL
Intervention: Add-on melatonin
Number of subjects: 31

Group type: COMPARATOR
Intervention: Add-on placebo
Number of subjects: 31
Study: 15159366

Group type: EXPERIMENTAL
Intervention: Adverse events (AEs) identified by physician reviewers
Number of subjects: 3745

Group type: EXPERIMENTAL
Intervention: Preventable adverse events
Number of subjects: 3745

Group type: EXPERIMENTAL
Intervention: Adverse events leading to death
Number of subjects: 3745

Group type: EXPERIMENTAL
Intervention: Additional hospital days associated with AEs
Number of subjects: 3745

Group type: EXPERIMENTAL
Intervention: Comparison of age between patients with and without AEs
Number of subjects: 3745
Study: 10365191

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Treatment (CBT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Interactional Treatment (IT)
Number of subjects: 32